| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| review article | Q7318358 |
| P50 | author | Gerd Antes | Q1510394 |
| Guido Schwarzer | Q28360274 | ||
| Gerhild Becker | Q48084526 | ||
| Sabine Buroh | Q60696877 | ||
| Joerg J Meerpohl | Q38323848 | ||
| P2093 | author name string | Carola Xander | |
| Waldemar Siemens | |||
| P2860 | cites work | Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children | Q24197736 |
| Topical capsaicin (low concentration) for chronic neuropathic pain in adults | Q24200378 | ||
| Topical capsaicin (high concentration) for chronic neuropathic pain in adults | Q24200709 | ||
| Pharmacological interventions for pruritus in adult palliative care patients | Q24202000 | ||
| Droperidol for treatment of nausea and vomiting in palliative care patients | Q24234434 | ||
| Carbamazepine for acute and chronic pain in adults | Q24234776 | ||
| Opioid antagonists for alcohol dependence | Q24235797 | ||
| Magnesium sulphate and other anticonvulsants for women with pre-eclampsia | Q24236438 | ||
| Pregabalin for acute and chronic pain in adults | Q24239867 | ||
| Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data | Q24240202 | ||
| Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal | Q24240954 | ||
| Haloperidol for the treatment of nausea and vomiting in palliative care patients | Q24241412 | ||
| Topically applied anaesthetics for treating perineal pain after childbirth | Q24244004 | ||
| Opioid antagonists for alcohol dependence | Q24244900 | ||
| Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients | Q24245456 | ||
| Anticonvulsants for preventing seizures in patients with chronic subdural haematoma | Q24246569 | ||
| New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma | Q24615751 | ||
| Topical capsaicin--a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study | Q24669628 | ||
| Drug treatments for pruritus in adult palliative care | Q26825684 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| The neurobiology of itch | Q28247676 | ||
| How useful are systematic reviews for informing palliative care practice? Survey of 25 Cochrane systematic reviews | Q30483437 | ||
| The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus | Q33280833 | ||
| The pruritus of cholestasis | Q33545718 | ||
| Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram | Q33714954 | ||
| Systematic review of topical capsaicin in the treatment of pruritus | Q33762584 | ||
| Pruritus in advanced internal diseases. Pathogenesis and treatment | Q34118120 | ||
| Neurotropic and psychotropic drugs in dermatology | Q34129811 | ||
| Understanding pruritus in systemic disease | Q34166985 | ||
| Itch | Q34179853 | ||
| Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. | Q34320153 | ||
| Specific C-receptors for itch in human skin. | Q34441021 | ||
| Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement | Q34451391 | ||
| Itch and pruritus: what are they, and how should itches be classified? | Q34468701 | ||
| Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases | Q34505073 | ||
| Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus | Q34548118 | ||
| Uraemic pruritus--new perspectives and insights from recent trials | Q34799737 | ||
| Review article: pruritus in cholestatic and other liver diseases | Q35091959 | ||
| Pruritus: a review. | Q35160779 | ||
| Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis | Q36066753 | ||
| Pharmacologic advances in the systemic treatment of itch | Q36317067 | ||
| Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial | Q36350869 | ||
| Comparison of Gabapentin and Ketotifen in Treatment of Uremic Pruritus in Hemodialysis Patients. | Q36697791 | ||
| Neurophysiological and neurochemical basis of modern pruritus treatment. | Q37028291 | ||
| Pruritus in primary biliary cirrhosis: pathogenesis and therapy | Q37154326 | ||
| Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials | Q37244975 | ||
| Uraemic pruritus: clinical characteristics, pathophysiology and treatment. | Q37411113 | ||
| Management of the pruritus of cholestasis: potential role of opiate antagonists | Q37413047 | ||
| Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. | Q40004812 | ||
| Pharmacologic control of pruritus. | Q40245260 | ||
| Comparison of Avena sativa, vinegar, and hydroxyzine for uremic pruritus of hemodialysis patients: a crossover randomized clinical trial | Q40737230 | ||
| Pruritus associated with cholestasis. A review of pathogenesis and management | Q40801345 | ||
| Treatment of opioid-induced pruritus with ondansetron: report of four patients. | Q40928380 | ||
| A controlled trial of naloxone infusions for the pruritus of chronic cholestasis | Q41142015 | ||
| Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications | Q41445515 | ||
| A multicenter evaluation of cancer pain control by palliative care teams. | Q41531648 | ||
| Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial | Q41673941 | ||
| Effect of oral naltrexone on pruritus in cholestatic patients | Q41808544 | ||
| Subhypnotic doses of propofol relieve pruritus induced by epidural and intrathecal morphine | Q42042628 | ||
| Treatment of pruritus due to chronic obstructive liver disease | Q42174795 | ||
| Efficacy of topical hydrating and emollient lotion containing 10% urea ISDIN® plus dexpanthenol (Ureadin Rx 10) in the treatment of skin xerosis and pruritus in hemodialyzed patients: an open prospective pilot trial. | Q42618083 | ||
| The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients | Q42849981 | ||
| The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial | Q42947273 | ||
| Topical capsaicin therapy for uremic pruritus in patients on hemodialysis. | Q43092981 | ||
| Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease | Q43128687 | ||
| Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. | Q43223186 | ||
| Mirtazapine for pruritus | Q44340894 | ||
| Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies | Q44350825 | ||
| Treatment of pruritus caused by cholestasis with opioid antagonists | Q44351322 | ||
| Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. | Q44573504 | ||
| Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial | Q44679061 | ||
| A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy | Q44901262 | ||
| A comparative study on the effects of naltrexone and loratadine on uremic pruritus | Q44922690 | ||
| Cimetidine treatment of pruritus in polycythemia vera | Q45126134 | ||
| Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial | Q45170301 | ||
| The use of midazolam to treat itching in a terminally ill patient with biliary obstruction | Q45180886 | ||
| Montelukast for treatment of refractory pruritus in patients on hemodialysis | Q46052703 | ||
| Low-dose doxepin for treatment of pruritus in patients on hemodialysis. | Q46055854 | ||
| Gabapentin and uremic pruritus in hemodialysis patients | Q46124053 | ||
| Doxepin in the management of pruritus associated with allergic cutaneous reactions. | Q46313344 | ||
| A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients | Q46343813 | ||
| Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study | Q46371191 | ||
| A controlled trial of ondansetron in the pruritus of cholestasis | Q46424983 | ||
| Carbamazepine can be effective in alleviating tormenting pruritus in patients with hematologic malignancy | Q46681721 | ||
| Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study | Q46832897 | ||
| Symptoms in 400 patients referred to palliative care services: prevalence and patterns | Q47809454 | ||
| Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study | Q48069006 | ||
| Comparison of the efficacy and safety of zinc sulfate vs. placebo in the treatment of pruritus of hemodialytic patients: a pilot randomized, triple-blind study | Q48106996 | ||
| Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study | Q48381465 | ||
| Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients | Q48502316 | ||
| The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients | Q48722951 | ||
| Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. | Q48729261 | ||
| Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases | Q48773204 | ||
| Polymethylmethacrylate efficacy in reduction of renal itching in hemodialysis patients: crossover study and role of tumor necrosis factor-alpha | Q49208322 | ||
| Cholestyramine in uraemic pruritus | Q50318025 | ||
| One year long-term study on abuse liability of nalfurafine in hemodialysis patients. | Q52303256 | ||
| Ondansetron therapy for uremic pruritus in hemodialysis patients. | Q52864176 | ||
| Some statistical methods for use in assessing the adequacy of hemodialysis | Q52886727 | ||
| Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. | Q53662990 | ||
| Activated charcoal rediscovered. | Q55716257 | ||
| Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis | Q58803462 | ||
| Sertraline as a first-line treatment for cholestatic pruritus | Q61480066 | ||
| Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study | Q61854318 | ||
| Pruritus measurement and treatment | Q37421826 | ||
| Epidemiology of itch: adding to the burden of skin morbidity | Q37581426 | ||
| Antipruritic treatment with systemic μ-opioid receptor antagonists: a review | Q37749941 | ||
| Chronic pruritus – pathogenesis, clinical aspects and treatment | Q37789400 | ||
| Cancer and itch | Q37902322 | ||
| Topical therapies for pruritus | Q37902324 | ||
| Pruritus: management algorithms and experimental therapies. | Q37902325 | ||
| Pruritus in cutaneous T-cell lymphoma: a review | Q37979593 | ||
| Gabapentin for pruritus in palliative care | Q38007412 | ||
| GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes | Q38011509 | ||
| The role of ondansetron in the management of cholestatic or uremic pruritus--a systematic review | Q38021147 | ||
| GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes | Q38057046 | ||
| Pruritus in palliative care: Getting up to scratch | Q38428252 | ||
| Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). | Q38482468 | ||
| Nalfurafine hydrochloride to treat pruritus: a review | Q38501089 | ||
| The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial | Q39231261 | ||
| Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin | Q39244111 | ||
| Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis | Q39250061 | ||
| Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial | Q39259414 | ||
| Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial | Q39344418 | ||
| A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch | Q39397866 | ||
| Efficacy of pentoxifylline in the treatment of pruritic papular eruption of HIV-infected persons | Q39447146 | ||
| Pruritus in HIV-1 disease: therapy with drugs which may modulate the pattern of immune dysregulation | Q39458774 | ||
| Treatment of pruritus | Q39474114 | ||
| Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron | Q39476222 | ||
| Buprenorphine and hepatic pruritus. | Q39480587 | ||
| Pruritus associated with liver disease: propofol, a new therapeutic approach? | Q39485256 | ||
| Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia | Q39502479 | ||
| Topical capsaicin for treatment of hemodialysis-related pruritus | Q39504336 | ||
| Treatment of pruritus of primary biliary cirrhosis with rifampin | Q39511303 | ||
| Should the patient with generalized pruritus be evaluated for malignancy? | Q39527397 | ||
| Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial | Q39533520 | ||
| Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal | Q39570637 | ||
| Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. | Q39595436 | ||
| Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The role of plasma histamine and skin mast cells | Q67674262 | ||
| Electrical needle therapy of uremic pruritus | Q68833470 | ||
| Double-blind, placebo-controlled study of nicergoline in the treatment of pruritus in patients receiving maintenance hemodialysis | Q69589382 | ||
| Behavioural treatment of scratching in patients with atopic dermatitis | Q69658560 | ||
| Generalized pruritus and systemic disease | Q71071707 | ||
| Cimetidine for pruritus in Hodgkin's disease | Q71139592 | ||
| Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream | Q71322931 | ||
| Oral activated charcoal in patients with uremic pruritus | Q71759733 | ||
| Randomised crossover trial of naltrexone in uraemic pruritus | Q71849293 | ||
| Cholestyramine therapy in patients with a paucity of intrahepatic bile ducts | Q72299230 | ||
| Renal transplantation | Q72442105 | ||
| The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures | Q72533159 | ||
| Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial | Q72742589 | ||
| Uremic pruritus: roles of parathyroid hormone and substance P | Q73202115 | ||
| Itch-associated response induced by intradermal serotonin through 5-HT2 receptors in mice | Q73315533 | ||
| Effective treatment of pruritus with naltrexone, an orally active opiate antagonist | Q73805118 | ||
| The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression | Q73924500 | ||
| Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients | Q74522962 | ||
| PRURITUS | Q76776679 | ||
| Paroxetine for pruritus in advanced cancer | Q77297838 | ||
| Uremic pruritus: an unresolved problem in hemodialysis patients | Q77389389 | ||
| Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial | Q77609350 | ||
| Rifampicin as treatment for pruritus in malignant cholestasis | Q77617244 | ||
| Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study | Q78163535 | ||
| Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study | Q78554315 | ||
| A comparative trial of trimeprazine and amylobarbitone in pruritus | Q79518906 | ||
| Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus | Q79782064 | ||
| Treatment of pruritus with topically applied opiate receptor antagonist | Q79826087 | ||
| Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials | Q80215317 | ||
| Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus) | Q80311756 | ||
| Ondansetron and pruritus in chronic liver disease: a controlled study | Q80606942 | ||
| Gabapentin: a promising drug for the treatment of uremic pruritus | Q80750289 | ||
| Uremic pruritus: still an important clinical problem | Q80953407 | ||
| Lack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients | Q84096741 | ||
| [Antidepressant drugs : a reasonable therapy for pruritus?] | Q84281484 | ||
| Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients | Q84456276 | ||
| Therapeutic effect of oral nicotinamide on refractory uremic pruritus: a randomized, double-blind study | Q85748869 | ||
| P304 | page(s) | CD008320 | |
| P577 | publication date | 2016-11-16 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Pharmacological interventions for pruritus in adult palliative care patients | |
| P478 | volume | 11 |
| Q93068387 | Acute effects of ayahuasca in a juvenile non-human primate model of depression |
| Q64263706 | Brain allopregnanolone induces marked scratching behaviour in diet-induced atopic dermatitis mouse model |
| Q43004194 | Effect of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus on sleep disorders: a study protocol for single-arm, prospective, interventional study |
| Q33721771 | Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial |
| Q94397779 | Interventions for pruritus of unknown cause |
| Q47160206 | Investigating endogenous µ-opioid receptors in human keratinocytes as pharmacological targets using novel fluorescent ligand |
| Q55076872 | Pruritus: Progress toward Pathogenesis and Treatment. |
| Q42146844 | Treatment of pruritus in a palliative care patient with low-dose paroxetine: a case report |
| Q51353611 | Update in Hospice and Palliative Care. |
Search more.